Skylar Jeremias

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast Cancer

November 12, 2023

Video

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.

Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors

November 11, 2023

Article

The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.

Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases

November 09, 2023

Article

A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.

Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate

November 08, 2023

Article

Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.

Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study

November 07, 2023

Article

A Chinese randomized study in healthy participants found comparable pharmacokinetic, pharmacodynamic, and safety profiles between LY01011, a denosumab biosimilar, and its originator (Xgeva).

Biosimilar Business Roundup for October 2023—Podcast Edition

November 05, 2023

Podcast

On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.

The Top 5 Biosimilar Articles for the Week of October 30

November 03, 2023

Video

Here are the top 5 biosimilar articles for the week of October 30, 2023.

Physicians Agree on Safety of Biosimilars, Nonmedical Switching in IBD, Survey Says

November 02, 2023

Article

An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.

FDA Approves First Stelara Biosimilar, Wezlana

November 01, 2023

Article

The FDA approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference Stelara (ustekinumab). The biosimilar was also approved with an interchangeability designation.

Biosimilars Business Roundup: October 2023

November 01, 2023

Article

Between 3 regulatory approvals, 2 complete response letters, and new data and industry insights, October brought a number of business updates that have the potential to impact the entire US biosimilar industry.